These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

368 related articles for article (PubMed ID: 32522059)

  • 41. An international survey on the management of patients receiving CAR T-cell therapy for haematological malignancies on behalf of the Chronic Malignancies Working Party of EBMT.
    Hayden PJ; Sirait T; Koster L; Snowden JA; Yakoub-Agha I
    Curr Res Transl Med; 2019 Aug; 67(3):79-88. PubMed ID: 31182380
    [TBL] [Abstract][Full Text] [Related]  

  • 42. CAR-T Cell Therapy in Hematological Malignancies: Current Opportunities and Challenges.
    Zhang X; Zhu L; Zhang H; Chen S; Xiao Y
    Front Immunol; 2022; 13():927153. PubMed ID: 35757715
    [TBL] [Abstract][Full Text] [Related]  

  • 43. CAR-T Cell Therapy for Acute Lymphoblastic Leukemia: Transforming the Treatment of Relapsed and Refractory Disease.
    Pehlivan KC; Duncan BB; Lee DW
    Curr Hematol Malig Rep; 2018 Oct; 13(5):396-406. PubMed ID: 30120708
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Challenges and strategies for improving efficacy in CAR-T therapy].
    Uchibori R
    Rinsho Ketsueki; 2024; 65(6):597-602. PubMed ID: 38960662
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Chimeric antigen-receptor T-cell therapy for hematological malignancies and solid tumors: Clinical data to date, current limitations and perspectives.
    Gauthier J; Yakoub-Agha I
    Curr Res Transl Med; 2017 Sep; 65(3):93-102. PubMed ID: 28988742
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Novel xeno-free and serum-free culturing condition to improve piggyBac transposon-based CD19 chimeric antigen receptor T-cell production and characteristics.
    Sanyanusin M; Tudsamran S; Thaiwong R; Tawinwung S; Nishio N; Takahashi Y; Hirankarn N; Suppipat K
    Cytotherapy; 2023 Apr; 25(4):397-406. PubMed ID: 36517366
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Resistance Mechanisms to CAR T-Cell Therapy and Overcoming Strategy in B-Cell Hematologic Malignancies.
    Song MK; Park BB; Uhm JE
    Int J Mol Sci; 2019 Oct; 20(20):. PubMed ID: 31658644
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Immune Cell Hacking: Challenges and Clinical Approaches to Create Smarter Generations of Chimeric Antigen Receptor T Cells.
    Elahi R; Khosh E; Tahmasebi S; Esmaeilzadeh A
    Front Immunol; 2018; 9():1717. PubMed ID: 30108584
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Chimeric antigen receptor T-cell therapy for hematological malignancies].
    Nakazawa Y
    Rinsho Ketsueki; 2019; 60(9):1351-1357. PubMed ID: 31597863
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A novel generation 1928zT2 CAR T cells induce remission in extramedullary relapse of acute lymphoblastic leukemia.
    Weng J; Lai P; Qin L; Lai Y; Jiang Z; Luo C; Huang X; Wu S; Shao D; Deng C; Huang L; Lu Z; Zhou M; Zeng L; Chen D; Wang Y; Chen X; Geng S; Robert W; Tang Z; He C; Li P; Du X
    J Hematol Oncol; 2018 Feb; 11(1):25. PubMed ID: 29458388
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The Other Side of CAR T-Cell Therapy: Cytokine Release Syndrome, Neurologic Toxicity, and Financial Burden.
    Santomasso B; Bachier C; Westin J; Rezvani K; Shpall EJ
    Am Soc Clin Oncol Educ Book; 2019 Jan; 39():433-444. PubMed ID: 31099694
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Late relapse after CAR-T cell therapy for adult patients with hematologic malignancies: A definite evidence from systematic review and meta-analysis on individual data.
    Zinzi A; Gaio M; Liguori V; Cagnotta C; Paolino D; Paolisso G; Castaldo G; Nicoletti GF; Rossi F; Capuano A; Rafaniello C
    Pharmacol Res; 2023 Apr; 190():106742. PubMed ID: 36963592
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Supportive Care for Patients with Lymphoma Undergoing CAR-T-cell Therapy: the Advanced Practice Provider's Perspective.
    Granroth G; Rosenthal A; McCallen M; Coughlin C; Benson H; Palmer J; Castro JE; Munoz J
    Curr Oncol Rep; 2022 Dec; 24(12):1863-1872. PubMed ID: 36336769
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Allogeneic CD19-CAR-T cell infusion after allogeneic hematopoietic stem cell transplantation in B cell malignancies.
    Liu J; Zhong JF; Zhang X; Zhang C
    J Hematol Oncol; 2017 Jan; 10(1):35. PubMed ID: 28143567
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Strategies for Reducing Toxicity and Enhancing Efficacy of Chimeric Antigen Receptor T Cell Therapy in Hematological Malignancies.
    Wang H; Tang L; Kong Y; Liu W; Zhu X; You Y
    Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298069
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Predictive and therapeutic biomarkers in chimeric antigen receptor T-cell therapy: A clinical perspective.
    Mirzaei HR; Mirzaei H; Namdar A; Rahmati M; Till BG; Hadjati J
    J Cell Physiol; 2019 May; 234(5):5827-5841. PubMed ID: 30317583
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Anti-CD19 CAR-T cells: Digging in the dark side of the golden therapy.
    Bouziana S; Bouzianas D
    Crit Rev Oncol Hematol; 2021 Jan; 157():103096. PubMed ID: 33181441
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Clinical Efficacy and Tumor Microenvironment Influence in a Dose-Escalation Study of Anti-CD19 Chimeric Antigen Receptor T Cells in Refractory B-Cell Non-Hodgkin's Lymphoma.
    Yan ZX; Li L; Wang W; OuYang BS; Cheng S; Wang L; Wu W; Xu PP; Muftuoglu M; Hao M; Yang S; Zhang MC; Zheng Z; Li J; Zhao WL
    Clin Cancer Res; 2019 Dec; 25(23):6995-7003. PubMed ID: 31444250
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Preclinical and clinical advances in dual-target chimeric antigen receptor therapy for hematological malignancies.
    Guo Z; Tu S; Yu S; Wu L; Pan W; Chang N; Zhou X; Song C; Li Y; He Y
    Cancer Sci; 2021 Apr; 112(4):1357-1368. PubMed ID: 33416209
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells.
    Kueberuwa G; Zheng W; Kalaitsidou M; Gilham DE; Hawkins RE
    J Vis Exp; 2018 Oct; (140):. PubMed ID: 30394400
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.